These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 25306215)

  • 1. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
    Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors.
    Chio II; Yordanov G; Tuveson D
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25430851
    [No Abstract]   [Full Text] [Related]  

  • 3. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.
    Henry KE; Dacek MM; Dilling TR; Caen JD; Fox IL; Evans MJ; Lewis JS
    Clin Cancer Res; 2019 Jan; 25(1):166-176. PubMed ID: 30228208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
    Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
    Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma.
    Zhang M; Fan HY; Li SC
    Biomed Pharmacother; 2015 Jul; 73():123-8. PubMed ID: 26211592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53.
    Zhang Z; Li H; Deng Y; Schuck K; Raulefs S; Maeritz N; Yu Y; Hechler T; Pahl A; Fernández-Sáiz V; Wan Y; Wang G; Engleitner T; Öllinger R; Rad R; Reichert M; Diakopoulos KN; Weber V; Li J; Shen S; Zou X; Kleeff J; Mihaljevic A; Michalski CW; Algül H; Friess H; Kong B
    Gastroenterology; 2021 Nov; 161(5):1601-1614.e23. PubMed ID: 34303658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations.
    Sawai Y; Kodama Y; Shimizu T; Ota Y; Maruno T; Eso Y; Kurita A; Shiokawa M; Tsuji Y; Uza N; Matsumoto Y; Masui T; Uemoto S; Marusawa H; Chiba T
    Cancer Res; 2015 Aug; 75(16):3292-301. PubMed ID: 26113087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trisomy of the Dscr1 gene suppresses early progression of pancreatic intraepithelial neoplasia driven by oncogenic Kras.
    Lee JC; Shin J; Baek KH
    Biochem Biophys Res Commun; 2013 Oct; 440(1):50-5. PubMed ID: 24041692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model.
    Siddique HR; Liao DJ; Mishra SK; Schuster T; Wang L; Matter B; Campbell PM; Villalta P; Nanda S; Deng Y; Saleem M
    Int J Cancer; 2012 Oct; 131(7):1720-31. PubMed ID: 22190076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.
    Diersch S; Wirth M; Schneeweis C; Jörs S; Geisler F; Siveke JT; Rad R; Schmid RM; Saur D; Rustgi AK; Reichert M; Schneider G
    Oncogene; 2016 Jul; 35(29):3880-6. PubMed ID: 26592448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor-targeted radionuclide-PNA-peptide chimeras.
    Tian X; Chakrabarti A; Amirkhanov NV; Aruva MR; Zhang K; Mathew B; Cardi C; Qin W; Sauter ER; Thakur ML; Wickstrom E
    Ann N Y Acad Sci; 2005 Nov; 1059():106-44. PubMed ID: 16382049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse Models of Pancreatic Ductal Adenocarcinoma.
    Ponz-Sarvise M; Tuveson DA; Yu KH
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.
    Sureban SM; May R; Weygant N; Qu D; Chandrakesan P; Bannerman-Menson E; Ali N; Pantazis P; Westphalen CB; Wang TC; Houchen CW
    Cancer Lett; 2014 Aug; 351(1):151-61. PubMed ID: 24880079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
    Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
    Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis.
    Matsuura T; Maru Y; Izumiya M; Hoshi D; Kato S; Ochiai M; Hori M; Yamamoto S; Tatsuno K; Imai T; Aburatani H; Nakajima A; Hippo Y
    Carcinogenesis; 2020 Jun; 41(4):490-501. PubMed ID: 31233118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.